About Pyrazine-2-carboxylic acid, If you have any questions, you can contact Pang, HY; Wang, N; Chai, JL; Wang, XY; Zhang, YH; Bi, Z; Wu, WB; He, G or concate me.. SDS of cas: 98-97-5
Pang, HY; Wang, N; Chai, JL; Wang, XY; Zhang, YH; Bi, Z; Wu, WB; He, G in [Pang, Haiying; Wang, Ning; Chai, Jinlong; Wang, Xiaoyun; Zhang, Yuehua; Bi, Zhiang; He, Gu] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China; [Pang, Haiying; Wang, Ning; Chai, Jinlong; Wang, Xiaoyun; Zhang, Yuehua; Bi, Zhiang; He, Gu] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China; [Pang, Haiying; Wang, Ning; Chai, Jinlong; Wang, Xiaoyun; Zhang, Yuehua; Bi, Zhiang; He, Gu] Collaborat Innovat Ctr, Chengdu 610041, Sichuan, Peoples R China; [Wu, Wenbin] Chongzhou Peoples Hosp, Dept Neurol, Chengdu 611230, Peoples R China published Discovery of novel TNNI3K inhibitor suppresses pyroptosis and apoptosis in murine myocardial infarction injury in 2020, Cited 49. SDS of cas: 98-97-5. The Name is Pyrazine-2-carboxylic acid. Through research, I have a further understanding and discovery of 98-97-5.
Myocardial infarction (MI) injury is a highly lethal syndrome that has, until recently, suffered from a lack of clinically efficient targeted therapeutics. The cardiac troponin I interacting kinase (TNNI3K) exacerbates ischemia-reperfusion (IR) injury via oxidative stress, thereby promoting cardiomyocyte death. In this current study, we designed and synthesized 35 novel TNNI3K inhibitors with a pyrido[4,5]thieno [2,3-d] pyrimidine scaffold. In vitro results indicated that some of the inhibitors exhibited sub-micromolar TNNI3K inhibitory capacity and good kinase selectivity, as well as cytoprotective activity, in an oxygen-glucose deprivation (OGD) injury cardiomyocyte model. Furthermore, investigation of the mechanism of the representative derivative compound 6o suggested it suppresses pyroptosis and apoptosis in cardiomyocytes by interfering with p38MAPK activation, which was further confirmed in a murine myocardial infarction injury model. In vivo results indicate that compound 6o can markedly reduce myocardial infarction size and alleviate cardiac tissue damage in rats. In brief, our results provide the basis for further development of novel TNNI3K inhibitors for targeted MI therapy. (C) 2020 Elsevier Masson SAS. All rights reserved.
About Pyrazine-2-carboxylic acid, If you have any questions, you can contact Pang, HY; Wang, N; Chai, JL; Wang, XY; Zhang, YH; Bi, Z; Wu, WB; He, G or concate me.. SDS of cas: 98-97-5
Reference:
Patent; Chevron Research Company; US4732894; (1988); A;,
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem